Imprint
Editor:
Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
Bad Homburg v. d. H.
Commercial register Bad Homburg v. d. H.
HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick
Represented by the general partner
Fresenius Management SE:
Management Board:
Dr. Ulf M. Schneider (Chairman)
Rainer Baule
Dr. Franceso De Meo
Dr. Jürgen Götz
Dr. Ben Lipps
Stephan Sturm
Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick
Commercial register Bad Homburg v. d. H.
HRB 11673
Ust-Ident-Number: DE 114152311
Contact for Shareholders:
Investor Relations
Telephone: ++49 6172 6 08-2637
Telefax: ++49 6712 6 08-2488
e-mail: ir-fre@fresenius.com
Contact for Journalists:
Corporate Communications
Telephone: ++49 6172 6 08-2302
Telefax: ++49 6712 6 08-2294
e-mail: pr-fre@fresenius.com
Postal address:
Fresenius SE & Co. KGaA
61346 Bad Homburg v. d. H.
Germany
The German version of this Annual Report is legally binding.
The Annual Report, the financial statements of Fresenius SE & Co. KGaA and the consolidated statements in accordance with IFRS accounting principles are available on our website and may be obtained upon request at Investor Relations.
You will find further information and current news about our company on our website at: http://www.fresenius.com.
FORWARD-LOOKING STATEMENTS:
This Annual Report contains forward-looking statements. These statements represent assessments which we have made on the basis of the information available to us at the time. Should the assumptions on which the statements are based on not occur, or if risks should arise – as mentioned in the risk report and the SEC filings of Fresenius Medical Care AG & Co. KGaA and Fresenius Kabi Pharmaceuticals Holding, Inc. – the actual results could differ materially from the results currently expected.